## CITATION REPORT List of articles citing

Drug reaction with eosinophilia and systemic symptoms syndrome to hydroxychloroquine, an old drug in the spotlight in the COVID-19 era

DOI: 10.1111/dth.13499 Dermatologic Therapy, 2020, 33, e13499.

Source: https://exaly.com/paper-pdf/76583269/citation-report.pdf

Version: 2024-04-23

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
18	A case report of toxic epidermal necrolysis (TEN) in a patient with COVID-19 treated with hydroxychloroquine: are these two partners in crime?. <i>Clinical and Molecular Allergy</i> , <b>2020</b> , 18, 19	3.7	12
17	Drug reaction with eosinophilia and systemic symptoms syndrome in a patient with COVID-19. Journal of the European Academy of Dermatology and Venereology, <b>2020</b> , 34, e768-e700	4.6	14
16	Hydroxychloroquine. <i>Reactions Weekly</i> , <b>2020</b> , 1826, 153-153	О	
15	A generalized purpuric eruption with histopathologic features of leucocytoclastic vasculitis in a patient severely ill with COVID-19. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2020</b> , 34, e579-e581	4.6	23
14	First case of DRESS syndrome caused by hydroxychloroquine with a positive patch test. <i>Contact Dermatitis</i> , <b>2021</b> , 84, 50-51	2.7	5
13	COVID-19: The experience from Iran. Clinics in Dermatology, <b>2021</b> , 39, 23-32	3	5
12	Generalized exanthema due to hydroxychloroquine during COVID-19 prophylaxis. <i>International Journal of Clinical Practice</i> , <b>2021</b> , 75, e13793	2.9	
11	Toxicity of chloroquine and hydroxychloroquine following therapeutic use or overdose. <i>Clinical Toxicology</i> , <b>2021</b> , 59, 12-23	2.9	24
10	Purpuric Skin Rash in a Patient Undergoing Pfizer-BioNTech COVID-19 Vaccination: Histological Evaluation and Perspectives. <i>Vaccines</i> , <b>2021</b> , 9,	5.3	3
9	HMGB1-TIM3-HO1: A New Pathway of Inflammation in Skin of SARS-CoV-2 Patients? A Retrospective Pilot Study. <i>Biomolecules</i> , <b>2021</b> , 11,	5.9	4
8	Behavior of Eosinophil Counts in Recovered and Deceased COVID-19 Patients over the Course of the Disease. <i>Viruses</i> , <b>2021</b> , 13,	6.2	3
7	Severe and life-threatening COVID-19-related mucocutaneous eruptions: A systematic review. <i>International Journal of Clinical Practice</i> , <b>2021</b> , e14720	2.9	5
6	Manifestaciones dermatolgicas de COVID-19: ¿casualidad o causalidad?. 34, 34-41		1
5	A temporal cluster of cutaneous drug eruptions developing after initiation of hydroxychloroquine <i>Scandinavian Journal of Rheumatology</i> , <b>2022</b> , 1-3	1.9	О
4	Herpesvirus and neurological manifestations in patients with severe coronavirus disease. <i>Virology Journal</i> , <b>2022</b> , 19,	6.1	1
3	Nutrition as Personalized Medicine against SARS-CoV-2 Infections: Clinical and Oncological Options with a Specific Female Groups Overview. <b>2022</b> , 23, 9136		5
2	Manifestaciones dermatolgicas asociadas a la gravedad de la infecci por COVID-19. Estudio observacional transversal retrospectivo de 144 pacientes. <b>2022</b> ,		O

1 Viral infections and drug hypersensitivity.

О